$300.43 Million in Sales Expected for Insulet Co. (NASDAQ:PODD) This Quarter

Brokerages expect Insulet Co. (NASDAQ:PODD) to post $300.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Insulet’s earnings, with the highest sales estimate coming in at $308.50 million and the lowest estimate coming in at $297.60 million. Insulet posted sales of $246.10 million during the same quarter last year, which suggests a positive year-over-year growth rate of 22.1%. The company is scheduled to report its next earnings report after the market closes on Wednesday, February 23rd.

On average, analysts expect that Insulet will report full-year sales of $1.09 billion for the current year, with estimates ranging from $1.09 billion to $1.10 billion. For the next year, analysts expect that the business will report sales of $1.27 billion, with estimates ranging from $1.25 billion to $1.28 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 4th. The medical instruments supplier reported $0.18 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.07). The business had revenue of $275.60 million for the quarter, compared to analyst estimates of $272.62 million. Insulet had a positive return on equity of 0.63% and a negative net margin of 2.84%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.17 earnings per share.

Several equities research analysts recently commented on the company. Zacks Investment Research cut Insulet from a “hold” rating to a “strong sell” rating and set a $238.00 target price on the stock. in a report on Monday, January 10th. Citigroup boosted their target price on Insulet from $325.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, November 5th. Piper Sandler boosted their target price on Insulet from $262.00 to $295.00 and gave the stock a “neutral” rating in a report on Friday, November 5th. They noted that the move was a valuation call. Raymond James boosted their target price on Insulet from $285.00 to $329.00 and gave the stock an “outperform” rating in a report on Monday, November 8th. Finally, boosted their target price on Insulet from $300.00 to $330.00 and gave the stock a “buy” rating in a report on Friday, November 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Buy” and a consensus target price of $307.90.

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. Thrivent Financial for Lutherans increased its holdings in shares of Insulet by 483.4% in the third quarter. Thrivent Financial for Lutherans now owns 540,073 shares of the medical instruments supplier’s stock valued at $153,505,000 after buying an additional 447,492 shares in the last quarter. Capital Research Global Investors raised its stake in Insulet by 5.0% during the 3rd quarter. Capital Research Global Investors now owns 7,231,748 shares of the medical instruments supplier’s stock valued at $2,055,443,000 after purchasing an additional 343,978 shares during the period. Amundi acquired a new stake in Insulet during the 2nd quarter valued at $92,870,000. Janus Henderson Group PLC raised its stake in Insulet by 48.0% during the 3rd quarter. Janus Henderson Group PLC now owns 853,753 shares of the medical instruments supplier’s stock valued at $242,661,000 after purchasing an additional 277,056 shares during the period. Finally, UBS Asset Management Americas Inc. raised its stake in Insulet by 39.0% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 335,104 shares of the medical instruments supplier’s stock valued at $91,989,000 after purchasing an additional 94,086 shares during the period.

Shares of NASDAQ PODD opened at $242.71 on Friday. The company has a current ratio of 5.72, a quick ratio of 4.58 and a debt-to-equity ratio of 2.52. The stock has a 50 day simple moving average of $277.56 and a 200-day simple moving average of $285.16. The company has a market cap of $16.74 billion, a PE ratio of -539.36 and a beta of 0.67. Insulet has a 12-month low of $218.28 and a 12-month high of $324.81.

About Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

Read More: The risks of owning bonds

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.